Investor Relations
Feb 05, 2019
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes MORE >>
Feb 04, 2019
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes MORE >>
Feb 01, 2019
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer MORE >>
Jan 31, 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator MORE >>

Press Releases

All Releases
OPKO Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Purchase of Shares by Dr. Phillip Frost
Mar 23, 2009
MIAMI, Mar 23, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext U.S.:OPK) today announced that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the purchase of additional
OPKO Health, Inc. Announces Hart-Scott-Rodino Filing for Purchase of Shares by Dr. Phillip Frost
Mar 16, 2009
MIAMI, Mar 16, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext U.S.:OPK) today announced Phillip Frost, M.D., Chairman and CEO of the Company, has filed a Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR" Act), to allow him to purchase
OPKO Health Announces Update on Phase III Clinical Trial of Bevasiranib
Mar 06, 2009
MIAMI, Mar 06, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext US:OPK)today announced that, following the recommendation of the Independent Data Monitoring Committee (IDMC), it had decided to terminate its Phase III clinical study of Bevasiranib, a first-in-class siRNA, for the treatment
OPKO To Present Data on Next Generation Anti-Angiogenic VEGF165b-Sparing siRNA at Association for Research and Vision in Ophthalmology (ARVO 2009) Meeting
Feb 10, 2009
MIAMI, Feb 10, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext US:OPK) today announced that it will present initial data on the characterization of its next generation anti-VEGF siRNA molecules. These new proprietary siRNA's are designed to inhibit the angiogenic Vascular Endothelial
OPKO Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System
Jan 23, 2009
MIAMI, Jan 23, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext US:OPK) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to begin marketing in the United States its Spectral OCT SLO Combination Imaging System.
OPKO Health Initiates Clinical Trial of the Aquashunt(TM) to Treat Glaucoma
Jan 22, 2009
MIAMI, Jan 22, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) announced today that it has begun treating patients in a clinical trial of its Aquashunt(TM), a device for the treatment of refractory open angle glaucoma. The study, at two academic departments of ophthalmology, is designed to
OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD
Dec 04, 2008
MIAMI, Dec 04, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) announced today that it has completed enrollment in the Company's Phase III clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD). The multi-national study has enrolled more than 330
OPKO Acquires Worldwide Ophthalmic Rights to Teva's Budesonide for Inflammatory and Allergic Ocular Conditions
Oct 02, 2008
Offers Potential for Broad Spectrum Ocular Use
OPKO Health to Present at UBS 2008 Global Life Sciences Conference
Sep 17, 2008
MIAMI, Sep 17, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) today announced that senior management will present at the UBS 2008 Global Life Sciences Conference on Tuesday, September 23, 2008 at 1:00 PM EDT. The conference will be held at the Grand Hyatt New York in New York City.
Investors Led by The Frost Group Agree to Make $15 Million Investment in OPKO Health
Aug 08, 2008
MIAMI, Aug 08, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) today announced that a group of investors led by members of The Frost Group, a private investment group controlled by Dr. Phillip Frost, M.D., Chairman and CEO of OPKO, have agreed to make a $15 million investment in the Company.
OPKO Health, Inc. Set to Join Russell 3000 Index
Jun 17, 2008
MIAMI, Jun 17, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) today announced that it is set to join the broad-market Russell 3000(R) Index when Russell Investment Group reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2008, according to a preliminary
OPKO Acquires Rights to Novel Phase II Agent to Treat Viral Conjunctivitis
Jun 12, 2008
--Novel Agent Has Demonstrated Good Safety and Antiviral Activity in Viral Conjunctivitis--
--Unique Combination of Anti-Infective and Anti-Inflammatory Properties Offers Potential for Broad-Based Ocular Applications--
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Jun 03, 2008
- Study Published in Journal Molecular Vision -
- Results Show Good Distribution of Bevasiranib to Retina and RPE Cells after a Single Intravitreal Injection -
OPKO Health Acquires Company Developing Novel Glaucoma Therapy
May 07, 2008
-Vidus Ocular's Innovative Aquashunt(TM) Device Offers Potential Advantages-
-Glaucoma Affects 2.4 Million Americans and 60 Million People Worldwide-
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Mar 18, 2008
-Second Issued Patent for Bevasiranib Broadly Covers siRNA Targeting of VEGF Expression, Further Strengthening OPKO's RNAi Intellectual Property Portfolio-
OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
Feb 25, 2008
-In Vitro Data Shows OPKO's Formulation of NCT Has Promising Activity Against Acanthamoeba Keratitis, a Serious Ocular Infection- -Provides Additional Evidence That This Phase II Agent Has Good Tolerability and Broad Anti-Microbial Activity Against a Wide Range of Pathogens-
OPKO Health Announces Changes to Board of Directors
Jan 25, 2008
MIAMI, Jan 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced the appointment of Thomas E. Beier and Richard C. Pfenniger, Jr. to its Board of Directors. The company also announced the resignation of former Board member David Eichler. Mr.
OPKO Health to Present at 2008 Wachovia Healthcare Conference
Jan 23, 2008
MIAMI, Jan 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that it will present at the 2008 Wachovia Healthcare Conference on Wednesday, January 30, 2008 at 11:15 am EST. The conference will be held at the Langham Hotel in Boston.
OPKO Health Appoints Industry Veteran Dr. Naveed Shams as Chief Medical Officer
Jan 14, 2008
MIAMI, Jan 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that Naveed Shams, M.D., Ph.D., has joined OPKO as its Chief Medical Officer and Senior Vice President of Research and Development. Dr.
OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
Dec 06, 2007
MIAMI, Dec 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today reported that the gene silencing agent bevasiranib, OPKO's lead compound for the treatment of wet age-related macular degeneration (wet AMD), was named one of the top five most promising drugs
Displaying 341 - 360 of 373